Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders have also been butting heads in the GLP-1 weight loss space. Eli Lilly's ...

Novo Holdings, parent company of the pharmaceutical giant Novo Nordisk, is spending $16.5 billion on the acquisition. The ...

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...

Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Novo Nordisk unveils a $1.2 billion production facility in Denmark and finalizes Catalent acquisition, with financial and ...

Find insight on Novo Holdings, Malaysian glove sector and more in the latest Market Talks covering health care.

Novo Nordisk plans to invest $1.2 billion in a new production site for rare-disease medicines in Denmark. The Danish pharmaceutical giant said it will establish a production facility in Odense ...

Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...